Acrivon Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.47.

EBIT: As of FY2025 Q3, the actual value is USD -21.19 M.

Net Loss

• Net loss for the quarter ended September 30, 2025 was $18.2 million compared to a net loss of $22.4 million for the same period in 2024.

Research and Development Expenses

• Research and development expenses were $13.6 million for the quarter ended September 30, 2025, compared to $18.9 million for the same period in 2024.

General and Administrative Expenses

• General and administrative expenses were $6.0 million for the quarter ended September 30, 2025, which is materially consistent with $6.3 million for the same period in 2024.

Cash, Cash Equivalents, and Marketable Securities

• As of September 30, 2025, the company had cash, cash equivalents, and investments of $134.4 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027.

Outlook / Guidance

• Acrivon Therapeutics expects to provide an update on the registrational-intent trial and confirmatory trial design for ACR-368 in the second half of 2025. The company also plans to report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025 and advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025.